The assessment of cardioprotective effect of dexrazoxane (ICRF-187) againts late antrhracycline cardiotoxicity in patients treated for childhood cancer

ELBL, Lubomír, Hana HRSTKOVÁ, Jan NOVOTNÝ a Václav CHALOUPKA. The assessment of cardioprotective effect of dexrazoxane (ICRF-187) againts late antrhracycline cardiotoxicity in patients treated for childhood cancer. European Journal of Echocardiography. A Harcourt Healt Sciencec Company, 2003, roč. 2002, č. 3, s. 26. ISSN 1525-2167.

Základní údaje

Originální název

The assessment of cardioprotective effect of dexrazoxane (ICRF-187) againts late antrhracycline cardiotoxicity in patients treated for childhood cancer

Název anglicky

The assessment of cardioprotective effect of dexrazoxane (ICRF-187) against late anthracycline cardiotoxicity in patients treated for childhood cancer.

Autoři

ELBL, Lubomír, Hana HRSTKOVÁ, Jan NOVOTNÝ a Václav CHALOUPKA

Vydání

European Journal of Echocardiography, A Harcourt Healt Sciencec Company, 2003, 1525-2167

---

Další údaje

Typ výsledku

Článek v odborném periodiku

Utajení

není předmětem státního či obchodního tajemství

Organizační jednotka

Lékařská fakulta

---

Anotace

Anglicky

Clinical cardiotoxicity was found in 4 pts (5%) from group II. After exclusion of these patients wd have not found any difference in rest EF among groups. MPI was worsened in both groups in the compařrison to the controls (p-0,01) and IRT was prolonged in group II (p-0,05)). The increment in EF to dynamic stress was similar in pts and controls (12% group I,16% group II, 18% controls). On the contrary, debulamine stress revealed in 63% of cases the pathological response in patients. An inadequate response of MPI and ESS was present in pts withouuuut cardioprotection.